Archive
1321 articles, sorted by publication time.
Histotype Px will be evaluated in the PEGASUS and AlfaOmega clinical populations to determine whether it can add independent information about recurrence risk beyond postoperative ctDNA; the collaboration remains at the validation stage and has not yet demonstrated improved treatment outcomes.
Aletta can locate a vein and collect blood on its own, but this does not mean healthcare without human staff: it is currently limited to adult outpatient use, and every procedure must still be initiated and supervised by a trained phlebotomist.
The research team learned the relationship between protein sequences and surface expression from hundreds of experimental datasets, identifying 7 candidates from 3,700 computer-generated designs that performed on par with potent natural components; however, the findings currently remain limited to cell-based experiments.
A polymer–lipid carrier that requires neither antibody targeting nor prior T-cell stimulation delivers CAR instructions to splenic T cells and clears pathogenic fibroblasts in cancer and fibrosis models; hurdles in delivery, safety, and durability of efficacy remain before human application.
The research team packaged antigen mRNA, STING protein mRNA, and a delayed-release activator into the same lipid nanoparticle, seeking to resolve the paradox in which premature activation of innate immunity instead reduces antigen production; the benefits in tumor control and survival currently remain limited to mouse experiments.
Antibodies submitted by 29 teams underwent standardized experimental testing, with some designs achieving picomolar affinity; however, leading methods often failed when applied to a different task, and simple statistics were even more reliable than most AI approaches.
The research team used the more active immunoproteasome inside cancer cells as a switch to selectively release the potent cytotoxic molecule MMAE. Tumors in mice shrank markedly, with good short-term tolerability, but hurdles involving drug distribution, immune safety, and the therapeutic window remain before human trials can begin.
A Phase 3 trial showed that blocking Activin A can substantially reduce new heterotopic bone lesions in adults; the approval expands treatment options for the ultra-rare disease FOP, but long-term functional benefits and suitability for children remain to be confirmed.
The latest additions are four lots of Gammaked, Gamunex-C, and Yimmugo. This is not a blanket suspension of immune globulin products, but healthcare facilities must immediately quarantine affected inventory.
A research team used plasma proteins from more than 60,000 people to build cell type-specific aging clocks that identified disease and mortality risks over up to 15 years of follow-up. However, the tool remains for research use and cannot yet replace diagnosis or prove that aging causes disease.
For persistent hypoglycemia following gastric bypass surgery, this once-daily injectable GLP-1 receptor antagonist met its primary and secondary endpoints in a 78-person trial; before a marketing application is submitted, full data are still needed to clarify the magnitude of efficacy and long-term safety.
The new guidance brings common challenges scattered across review meetings, manufacturing requirements, and clinical trial design into a single roadmap. It can help new teams avoid procedural gaps, but cannot replace early communication with the FDA about individual products.